IP Library Granted Patent US 9,200,264
Granted Patent B2
US 9,200,264 · App. 13/848,561 · Granted Dec 1, 2015

Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,200,264
App. No.
13/848,561
Granted
Dec 1, 2015
Kind
B2
Abstract

This invention provides compositions of active highly phosphorylated lysosomal sulfatase enzymes, their pharmaceutical compositions, methods of producing and purifying such lysosomal sulfatase enzymes and compositions and their use in the diagnosis, prophylaxis, or treatment of diseases and conditions, including particularly lysosomal storage diseases that are caused by, or associated with, a deficiency in the lysosomal sulfatase enzyme.

Claims (20)

1. A method for measuring the activity of a recombinant human lysosomal enzyme to degrade natural substrates, comprising:

(a) culturing an isolated human cell deficient in the lysosomal enzyme under conditions in which natural substrates for the lysosomal enzyme accumulate;

(b) contacting the cell with the lysosomal enzyme;

(c) lysing the cell;

(d) adding to the cell lysate an enzyme that (i) is specific for natural substrates and (ii) cleaves small oligosaccharides from the natural substrates;

(e) labeling the small oligosaccharides with a detectable moiety;

(f) optionally separating the labeled small oligosaccharides;

(g) detecting the labeled small oligosaccharides; and

(h) determining the activity of the lysosomal enzyme to degrade natural substrates by comparing (i) the amount of labeled small oligosaccharides from cells contacted with the lysosomal enzyme with (ii) the amount of labeled small oligosaccharides from cells not contacted with the lysosomal enzyme, wherein a reduction in (h)(i) as compared to (h)(ii) indicates the activity of the lysosomal enzyme to degrade natural substrates.

2. The method of claim 1 , wherein the lysosomal enzyme is a lysosomal sulfatase enzyme selected from the group consisting of, iduronate-2-sulfatase (IDS), sulfamidase/heparin-N-sulfatase (SGSH), N-acetylglucosamine-sulfatase (G6S) and N-acetylgalactosamine-6-sulfatase (GALNS).

3. The method of claim 2 , wherein the lysosomal sulfatase enzyme is GALNS.

4. The method of claim 1 , wherein the lysosomal enzyme is α-L-iduronidase (IDU).

5. The method of claim 1 , wherein the lysosomal enzyme is acid α-glucosidase (GAA).

6. The method of claim 1 , wherein the lysosomal enzyme is β-glucuronidase (GUSB).

7. The method of claim 1 , wherein the lysosomal enzyme is β-galactosidase (GLB1).

8. The method of claim 2 , wherein the lysosomal sulfatase enzyme is IDS.

9. The method of claim 2 , wherein the lysosomal sulfatase enzyme is SGSH.

10. The method of claim 2 , wherein the lysosomal sulfatase enzyme is G6S.

11. The method of claim 3 , wherein the natural substrates are keratan sulfate (KS) substrates.

12. The method of claim 11 , wherein the enzyme in step (d) is Keratanase II and the small oligosaccharides in step (d) are KS disaccharides.

Assignments (2)
SECURITY INTEREST Recorded Apr 27, 2026
From: BIOMARIN PHARMACEUTICAL INC.; AMICUS THERAPEUTICS, INC.
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 075493/0968 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 5, 2013
From: PUNGOR, ERNO; HAGUE, CHARLES; CHEN, ZHI
To: BIOMARIN PHARMACEUTICAL INC.
Reel/Frame 030944/0657 →